Physician profile
Michael W Chu
NPI 1235106881
$2,600.75
in general payments reported to CMS, 2019-2025
29 companies · $774 in 2025
The $774 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $226 · 2020: $155 · 2021: $211 · 2022: $296 · 2023: $359 · 2024: $579 · 2025: $774.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,712.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $445.32 | 2019-2025 | Lo Loestrin Fe, Orilissa |
| Sage Therapeutics, LLC | $253.84 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $240.19 | 2023-2025 | |
| Coopersurgical, INC. | $225.36 | 2019-2024 | Endosee |
| Mayne Pharma Commercial LLC | $184.28 | 2023-2025 | |
| Depuy Synthes Sales INC. | $140.56 | 2024-2025 | N/A, Speed Triad, Na |
| Hologic Sales and Service, LLC | $125.85 | 2019-2024 | Acessa Provu System |
| Sumitomo Pharma America, INC. | $122.44 | 2023-2024 | Myfembree, Gemtesa |
| Medtronic, INC. | $116.73 | 2024-2025 | Avalus, V-Loc 180 |
| Millicent US INC | $105.48 | 2024-2025 | Femring, Intrarosa, Femlyv |
| Stryker Corporation | $90.19 | 2025 | Iconix |
| Boston Scientific Corporation | $81.19 | 2019-2020 | |
| Conmed Corporation | $71.43 | 2021 | |
| Allergan, INC. | $46.16 | 2019-2020 | |
| Spr Therapeutics, INC | $38.21 | 2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $37.02 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $32.70 | 2021-2022 | |
| Organon LLC | $30.32 | 2021-2022 | |
| Scynexis, INC. | $29.24 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $22.82 | 2025 | |
| Roche Diagnostics Corporation | $21.97 | 2019 | |
| Pharmacosmos Therapeutics INC. | $21.62 | 2025 | Monoferric |
| Therapeuticsmd, INC. | $20.51 | 2022 | |
| Dysis Medical, INC. | $18.97 | 2023 | Dysis Ultra 2.0, Dysis V3 Digital Coploscope, Dysis View |
| Dexcom, INC. | $18.54 | 2025 | Dexcom G6 Transmitter |
| Evofem Biosciences, INC. | $15.96 | 2023 | Phexxi |
| Amag Pharmaceuticals, INC. | $15.35 | 2019 | |
| Ethicon US, LLC | $14.73 | 2025 | Stratafix |
| Aspira Women'S Health INC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.